| Current Price | $262.65 | Mkt Cap | $65.0B |
|---|---|---|---|
| Open | $255.82 | P/E Ratio | 26.61 |
| Prev. Close | $254.17 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $254.67 - $262.85 | Volume | 623,892 |
| 52-Wk Range | $176.36 - $292.75 | Avg. Daily Vol. | 1,735,381 |
The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.
| Current Price | $262.65 | Mkt Cap | $65.0B |
|---|---|---|---|
| Open | $255.82 | P/E Ratio | 26.61 |
| Prev. Close | $254.17 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $254.67 - $262.85 | Volume | 623,892 |
| 52-Wk Range | $176.36 - $292.75 | Avg. Daily Vol. | 1,735,381 |
The best Bull and Bear pitches based on recency and number of recommendations.
Great revenues and lots of potential new things in the pipeline. I’m specifically interested in their investments into genetic and stem cell treatments.
9/26/14 DOWN TO UP = <30.04> 7/19/16 = UP TO DOWN
Read the most recent pitches from players about VRTX.
Recs
dcrednek
(64.94)
Submitted: 4/18/2022 6:40:57 PM :
Start Price:
$282.99
NASDAQ:VRTX Score:
-0.02
Motley Fool Advisors top 10 pick for 4/18/22
Recs
tomfoolme
(30.62)
Submitted: 3/25/2022 2:03:36 PM :
Start Price:
$253.30
NASDAQ:VRTX Score:
+13.67
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States. 64B pe:27 div:- AS 180/10 Ry/y 27%
Recs
chessNstocks
(< 20)
Submitted: 3/9/2022 11:52:43 AM :
Start Price:
$239.32
NASDAQ:VRTX Score:
+14.64
From Zacks and Fidelity March 2022
Rev Change (Last Qtr vs Prior year Qtr) = 27.3%
Price/Sales (TTM) = 8.0
Find the members with the highest scoring picks in VRTX.
bugeyebear (49.76) Score: +1,465.89
The Score Leader is the player with the highest score across all their picks in VRTX.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| bugeyebear | 49.76 | 3/17/2008 |
|
3Y | $14.60 | +1,697.47% | +231.57% | +1,465.89 | 0 Comment | |
| lostontheprairie | 65.48 | 3/12/2008 |
|
5Y | $14.99 | +1,650.70% | +218.87% | +1,431.83 | 0 Comment | |
| Kudude | 62.70 | 3/12/2008 |
|
5Y | $14.99 | +1,650.70% | +218.87% | +1,431.83 | 0 Comment | |
| Salilp | 53.96 | 3/17/2008 |
|
5Y | $15.07 | +1,641.41% | +234.40% | +1,407.01 | 0 Comment | |
| davidmouw2 | < 20 | 3/14/2008 |
|
NS | $15.43 | +1,600.78% | +218.78% | +1,382.00 | 0 Comment | |
|
snazzysnazz | 71.93 | 3/13/2008 |
|
5Y | $15.49 | +1,594.19% | +226.57% | +1,367.62 | 0 Comment |
| NovaMechanika | 30.12 | 3/20/2008 |
|
3Y | $15.55 | +1,587.65% | +223.86% | +1,363.79 | 2 Comments | |
| stnewbie | 66.18 | 3/12/2008 |
|
NS | $15.78 | +1,563.05% | +220.32% | +1,342.73 | 0 Comment | |
| PrincetonAl | 90.54 | 3/7/2008 |
|
3Y | $15.86 | +1,554.67% | +226.52% | +1,328.15 | 1 Comment | |
|
|
hayrettin | 72.04 | 3/24/2008 |
|
5Y | $16.47 | +1,493.38% | +215.93% | +1,277.45 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
